PAREXEL Launches LIQUENT InSight® 6.0 Regulatory Information Management Platform

Tuesday, March 31, 2015

BOSTON, March 31, 2015 /PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today introduced the latest version of its Regulatory Information Management (RIM) platform: LIQUENT InSight® 6.0. The LIQUENT InSight platform supports the entire regulatory product lifecycle, from early planning of registration targets through product retirement, with robust submission planning, publishing, viewing and registration management capabilities.

While biopharmaceutical companies and the patients who can benefit from new drugs are located throughout the world, there is no single international regulatory body to review and approve new medicine applications.  For new and innovative medicines to successfully reach patients and maintain regulatory compliance throughout the product lifecycle, biopharmaceutical companies must navigate the complex, global regulatory and region-specific regulations.

"LIQUENT InSight 6.0 simplifies navigation of the global regulatory environment and provides the submission and registration management tools needed to more quickly bring treatments to market and effectively maintain them throughout their lifespan," said Xavier Flinois, President, PAREXEL Informatics. "As an essential part of the drug development journey, the LIQUENT InSight platform centralizes a company's regulatory information to drive standardization, improve collaboration, and helps to ensure compliance, eliminate waste, reduce costs, and increase efficiencies so more patients can quickly and safely receive the treatments they need."

Enhancements to the LIQUENT InSight platform include:

  • Business Intelligence: added robust analytics to enhance reporting capabilities
  • Usability: simplified interface designed by usability experts provide an intuitive experience to all levels of InSight users
  • Compliance: updated data model and architecture helps to ensure processes, output and work product compliance with standards such as XEVMPD and the upcoming IDMP mandate
  • Interoperability: revamped interoperability web services features that help systems interact and communicate with each other

Since the market introduction of LIQUENT InSight in 2004, more than 40 companies (including 14 of the top 20 pharmaceutical companies) have selected the LIQUENT InSight platform as their single source of regulatory information. PAREXEL's RIM technologies can also be coupled with comprehensive professional services from PAREXEL® Consulting, which provides a full complement of Regulatory Outsourcing Services to help companies meet the demands of today's complex and changing regulatory environment.  LIQUENT InSight 6.0 will also be available through the Perceptive® Partner Program.

About PAREXEL International

PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of expertise-based contract research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. PAREXEL Informatics provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 81 locations in 51 countries around the world, and has approximately 16,530 employees.  For more information about PAREXEL International visit

PAREXEL, PAREXEL Informatics, Perceptive, and LIQUENT InSight are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates.

This release contains "forward-looking" statements regarding future results and events.  For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements.  Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "should,"  "targets," and similar expressions are also intended to identify forward-looking statements.  The forward-looking statements in this release involve a number of risks and uncertainties.  The Company's actual future results may differ materially from the results discussed in the forward-looking statements contained in this release.  Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions, and to integrate newly acquired businesses including the acquisition of ClinIntel Limited, or enter into new lines of business; the impact on the Company's business of government regulation of the drug,  medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of foreign currency exchange rate fluctuations and other international economic, political, and other risks.   Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended December 31, 2015 as filed with the Securities and Exchange Commission on February 5, 2015, which "Risk Factors" discussion is incorporated by reference in this press release.  The Company specifically disclaims any obligation to update these forward-looking statements in the future.  These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.


Diana Martin, PAREXEL International           

Tel: +1 781-434-5516                                             


Cristi Barnett, PAREXEL International

Tel.: +1 781-434-4019


Matthew Briggs, PAN Communications      

Tel: +1 617-502-4300


To view the original version on PR Newswire, visit:

SOURCE PAREXEL International Corporation